MilliporeSigma is skilled in the art of GMP viral vector production and technology innovation, having manufactured viral vectors for over 20 years and producing more than 500 lots of drug substance from preclinical through commercial production. Our comprehensive portfolio of best-in-class bioprocessing products and technologies combined with our application expertise can help you quickly scale up to reach your process goals. Our BioReliance® testing services employ the broadest range of vector types to speed progress of gene therapy development.
MilliporeSigma - Gene Therapy
Related Resources
Cell and Gene Therapy Definitions for Raw Materials, Starting Materials, Drug Substance and Drug Product
The complexity of processes to manufacture cell and gene therapy medicinal products can cause confusion around definitions of raw materials, starting materials, process intermediates, drug substance and drug products. This document will discuss the...
CDMO Process Development Template
Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with scaling your viral vector.
Infographic - road map to commercialization
With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization of their therapies.